Diabetes and Endocrinology
Intensive HTN Treatment Cuts Early T2D Diagnosis-Linked CVD Event Risk
Intensive therapy reduces excess risk for CVD events associated with earlier diagnosis in women, but not men
Cabozantinib Promising for Metastatic Pheochromocytomas, Paragangliomas
Overall response rate was 25.0 percent in phase 2 study involving 17 patients
Cabozantinib Promising for Advanced Adrenocortical Carcinoma
Promising efficacy seen with a manageable safety profile in phase 2 study involving 18 patients
GLP1 Receptor Agonists Do Not Up Risk for Complications After Emergency Surgery
Risk for respiratory complications in patients with type 2 diabetes not increased with use of GLP1 receptor agonists
New School Lunch Rules Target Added Sugars, Salt
New Rules Mean 3.6 Million Americans Could Get Wegovy Via Medicare, Costing Billions
GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use
Seafood Consumption Tied to ‘Forever Chemical’ Exposure Risk
Consumers of seafood purchased in a local Northeastern U.S. market may be exposed to potentially risky PFAS concentrations
ACP: Time-Restricted Eating May Not Aid Weight Loss, Glycemic Measures
Findings seen in trial where calories were held constant for both groups
ACP: Recommendations Developed for Newer Type 2 Diabetes Medications
Strong recommendation given for addition of SGLT-2 or GLP-1 agonist to metformin and lifestyle modifications
